- Innovative Pharmaceutical Biotech has provided an update regarding Starcoin Group Limited's new memorandum of understanding with Newbridge Acquisition Limited and Conflux Foundation, aimed at exploring a potential de-SPAC transaction.
- This deal intends to facilitate Starcoin's access to U.S. capital markets and enhance its blockchain initiatives, potentially increasing value for shareholders if completed.
- The current analyst rating for Innovative Pharmaceutical Biotech stock is a Sell, with a price target of HK$0.18.
